1. What is it?
Kisspeptins are a family of related peptides. The number 10 identifies a fragment containing ten amino acids. Kisspeptin-10 and the longer kisspeptin-54 act on the same signalling system but differ structurally and may behave differently in the body. A paper referring simply to kisspeptin needs checking for the actual substance used. Findings on other family members cannot automatically be attributed to kisspeptin-10. [112] [113]
2. Why do people turn to it?
Kisspeptin-10 attracts interest from people seeking help with low testosterone, fertility problems or libido. Researchers are mainly examining whether it can stimulate reproductive hormone secretion. This includes disorders of the brain's control of the testes or ovaries. These are not a single disease with a single solution. Early experiments in healthy volunteers investigate the body's responses, but do not by themselves establish a treatment for infertility or an improvement in sex life. [112] [115]
3. How does it work?
Kisspeptin-10 affects the GnRH signal sent by a brain region called the hypothalamus. In response, the pituitary gland may increase release of LH and FSH, hormones that control the gonads: the ovaries and testes. In men, testosterone may also increase. However, the body regulates this system over time, rather than keeping every hormone as high as possible. Researchers therefore also track the rhythm of secretion and whether the response weakens over time. [112] [114]
4. What do studies actually show?
A 2011 study showed a clear hormonal response in healthy men. Another paper from the same year revealed an important difference in women: a response was visible before ovulation, but not under the conditions studied in the earlier cycle phase. This illustrates why saying it raises hormones is too general. The body's condition, the study population and the specific measurement matter; biological activity alone is not enough. [112] [113]
5. What do we still not know?
The largest gap is the move from hormonal changes to benefits that patients actually experience. Assessing infertility treatment requires appropriate studies of real outcomes, not just a temporary LH concentration. Similarly, a response in a healthy man does not prove effectiveness in a person with a condition. Small groups and short follow-up also make rare side effects difficult to assess. Findings for kisspeptin-54 should not be used to fill these gaps. [113] [115] [114]
6. What are the risks?
Early short studies did not reveal a large, clear safety signal, but they did not establish the safety of use over many months. The FDA also noted the possibility of unwanted immune reactions related to peptide quality and impurities. An effect on the hormonal system is precisely the intended action, not an incidental extra. Assessment must therefore cover both general symptoms and the consequences of hormonal changes for the individual, their conditions and their reproductive plans. [115] [113]
7. Is it an approved medicine?
Kisspeptin-10 remains a research substance for the uses discussed here. The FDA assessment document states that it is not an ingredient in a medicine approved by that agency. Reviewing a substance under procedures for pharmacy compounding does not establish clinical effectiveness. Publication of a new hormone experiment also does not automatically change its regulatory status. It should not be presented as an approved fertility treatment or a routinely recommended treatment for low testosterone. [115] [114]
8. What is new in research?
A study published on 3 August 2026 examined a longer-lasting hormonal response in healthy men. In one of the regimens studied, the response persisted for 12 days. This is a genuine new step in understanding the substance, but it remains part of a small physiological research programme. It did not assess whether treatment increases the chance of having a baby or provides lasting improvement in disease symptoms. The authors regard the finding as a basis for designing further studies. [114]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans
Physiological study in healthy women and men; online 5 October 2011; abstract and discussion reviewed in PMC · DOI: 10.1210/jc.2011-1408. Accessed: 3 November 2026.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
Human physiological study; 03.08.2026; full PubMed abstract read · DOI: 10.1093/ejendo/lvag134. Accessed: 03.11.2026.
- FDA Briefing Document: Kisspeptin-10 — Pharmacy Compounding Advisory Committee Meeting, October 29, 2024
Regulatory assessment before the 29.10.2024 meeting, not a medicine approval decision; substance identity, safety and effectiveness assessments, and conclusions were read. Accessed: 03.11.2026.
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
Small physiological study in healthy men; online 01.06.2011; abstract and selected methods and discussion from the full PMC text were read · DOI: 10.1210/jc.2011-0089. Accessed: 03.11.2026.